Please assess the completion status of the following clinical trial:

Trial Title: Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men or women age ≥18 years~* Histologically confirmed metastatic (stage IV) adenocarcinoma of the pancreas~* Measurable disease defined per RECIST~* Karnofsky Performance Status ≥50~* Expected survival ≥12 weeks~* Provide written informed consent~Exclusion Criteria:~* CNS metastases~* Prior treatment with other chemotherapy for pancreatic cancer unless used as a radiosensitizer~* Radiation therapy to \>25% of the bone marrow~* Clinically significant laboratory abnormalities~* Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix~* The need for chronic (i.e., \>7 days) oral or intravenous corticosteroid therapy with \>10mg/day prednisone equivalents~* Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol~* Patients who are within 28 days of radiation therapy, biologic therapy, immunotherapy, or other investigational medication. All side effects of prior treatment must have resolved at study entry.~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).